Jason Lettmann: Thank you, and welcome to our Q4 and fiscal year 2025 results call. We appreciate you all spending some time with us this morning. As usual, we will be making forward-looking ...
ALX Oncology Holdings reported a quarterly loss that exceeded analyst expectations, with an EPS of -$0.42 compared to a forecasted -$0.35. This 20% negative surprise led to a pre-market stock decline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results